Изучение фармакогенетических факторов, влияющих на эффективность и токсичность цисплатина при раке яичников
Диссертация
В результате все большую актуальность для современной химиотерапии приобретает индивидуальный подход к подбору препаратов и их доз, направленный на повышение эффективности и уменьшение токсичности имеющегося арсенала противоопухолевых средств. Поскольку традиционные прогностические факторы не позволяют предсказать, какие препараты окажутся эффективными у данного больного, выбор схем химиотерапии… Читать ещё >
Список литературы
- Калабрези П, Чабнер Б. Химиотерапия злокачественных новообразований. В кн.: Клиническая фармакология по Гудману и Гилману, 10-е изд. Пер. с англ. М.: Практика, 2006: 1067−125
- Переводчикова НИ (ред.). Руководство по химиотерапии опухолевых заболеваний. 2-е изд. М.: Практическая медицина, 2005.
- Попова СН, Сломинский ПА, Галушкин СН и др. Полиморфизм глута-тион-Б-трансфераз Ml и Т1 в ряде популяций России. Генетика 2001−38:281−4.
- Реброва ОЮ. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: Медиа Сфера, 2003.
- Abraham J, Earl НМ, Pharoah PD, Caldas С. Pharmacogenetics of cancer chemotherapy. Biochim Biophys Acta 2006−1766:168−83.
- Aletti GD, Gallenberg MM, Cliby WA, et al. Current management strategies for ovarian cancer. Mayo Clin Proc 2007−82:751−70.
- Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 2001−61:7130−5.
- Ambudkar SV, Kimchi-Sarfatyl C, Sauna 1 ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003- 22: 7468−85.
- Arbiser JL. Why targeted therapy hasn’t worked in advanced cancer. J Clin Invest 2007- 117:2762—5.
- Bentley DR. Genomes for medicine. Nature 2004−429:440−5.
- Bernig T, Chanock SJ. Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Rev Mol Diagn 2006−6:319−31.
- Bolt HM, Thier R. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr Drug Metab 2006−7:613−28.
- Bosch TM, Huitema ADR, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of do-cetaxel. Clin Cancer Res 2006−12:5786−93.
- Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol 2003- 38:107−17.
- Carson PE, Flanagan CL, Ickes CE, et al. Enzymatic deficiency in prinaquine-sensitive erythrocytes. Science 1956−124:484−5.
- Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007−25:2747−54.
- Coles BF, Morel F, Rauch C, et al. Effect of polymorphism in the human glutathione S-transferase Al promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 2001- 11:663−9.
- Dabholkar M, Bostick-Bruton F, Weber C, et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992−84:1512−7.
- Dabrowiak JC, Goodisman J, and Souid AK. Kinetic study of the reaction of cisplatin with thiols. Drug Metabol Dispos 2002−30:1378−84.
- Dasgupta RK, Adamson PJ, Davies FE, et al. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 2003−102:2345−50.
- Davies SM, Robison LL, Buckley JD, et al. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 2001−19:1279−87.
- Deeken JF, Figg WD, Bates SE, Sparreboom A. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs 2007- 18:111−26.
- Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005−107:155−76.
- Evans WE, McLeod HL. Pharmacogenomics — drug disposition, drug targets, and side effects. N Engl J Med 2003−348:538−48.
- Fehrmann RSN, Li X, van der Zee AGJ, et al. Profiling studies in ovarian cancer. Oncologist 2007−12:960−66.
- Felip E, Rosell R. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Rev Mol Diagn 2007−7:261−8.
- Garattini S, Bertele V. Efficacy, safety, and cost of new anticancer drugs. 5M/2002−325−269−71.
- Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006:58:521−90.
- Gately DP, Howell SB. Cellular accumulation of cisplatin. Br J Cancer 1993−67:1171−76.
- Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007−33:565−77.
- Green H, Soderkvist P, Rosenberg P, et al. MDR-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006−12:854−9.
- Guppy AE, Rustin GJS. CA 125 Response: Can it replace the traditional response criteria in ovarian cancer? Oncologist 2002−7:437−43.
- Gurney H, Wong M, Balleine RL, et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 2007−82:3310.
- Gurubhagavatula S, Liu G, Park W, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004−22:2594−601.
- Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005−45:51−88.
- Helleman J, van Staveren IL, Dinjens WN et al. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 2006−6:201.
- Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007−446:749−57.
- Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001 -411:366—74
- Holley SL, Rajagopal R, Hoban PR, et al. Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer. IntJ Oncol 2006−28:231—6.
- Holzer AK, Howell SB. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Research 2006−66:10 944−52.
- Hohaus S, Di Ruscio A, Di Febo A, et al. Glutathione S-transferase PI genotype and prognosis in Hodgkin’s lymphoma. Clin Cancer Res 2005−11:2175−9.
- Howells RE, Dhar KK, Hoban PR, et al. Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 overexpression, and outcome in epithelial ovarian cancer. Int J Gynecol Cancer 2004−14:242−50.
- Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 2007−26:183—201.
- Hughes HB, Biehl JP, Jones AP, et al. Metabolism of isoniazid in man as related to occurrence of peripheral neuritis. Am Rev Tuberc 1954- 70: 26 673.
- Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004−22:1382−8.
- Ishimoto TM, Ali-Osman F. Allelic variants of the human glutathione S-transferase PI gene confer differential cytoprotection against anticancer agents in E. coli. Pharmacogenetics 2002: 12: 543−53.
- Kang S, Ju W, Kim JW, et al. Association between ERCC1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med2006−38:320−4.
- Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature Rev Cancer 2007−7:573−584.
- Kim TW, Innocenti F. Insights, challenges, and future directions in irinoge-netics. Ther Drug Monit 2007−29:265−70.
- Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A «silent» polymorphism in the MDR1 gene changes substrate specificity. Science 2007−315:525−28.
- Komatsu M, Sumizawa T, Mutoh M, et al. Copper transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Research 2000−60:1312−6.
- Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003- 22: 7537−52.
- Krynetski E, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003−22:7403−13.
- Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005- 31, 90−105.
- Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002−54:1271−94.
- Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001- 409: 860−921.
- Lecomte T, Landi B, Beaune P, et al. Glutathione S-Transferase PI polymorphism (Ilel05Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006- 12: 3050−56.
- Lee JM, Wu TM, Lee YC, et al. Association of GSTP1 polymorphism and survival for esophageal cancer. Clin Cancer Res 2005- 11:4749−53.
- Lewis DF. 57 varieties: the human cytochromes P450. Pharmacogenomics 2004−5:305−18.
- Lewis LD, Miller AA, Rosner GL, et al. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 2007−13:3302−11.
- Litwack G, Ketterer B, Arias IM. Ligandin: a hepatic protein which binds steroids, bilirubin, carcinogens and a number of exogenous organic anions. Nature 1971−234:466−7.
- Lyman GH. Economics of cancer care. J Oncol Pract 2007−3:113−4.
- Marsh S, King CR, McLeod HL. ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clin Cancer Res 2006−12:4127−9.
- Mathijssen RH, van Schaik RH. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment. Eur J Cancer 2006−42:141−8.
- Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and «P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001−22:1437−45.
- McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cis-platin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996−334:1−6.
- Mcllwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006−25:1639−48.
- Michael M, Doherty MM. Tumoral drug metabolism: overview and its implications for cancer therapy. J Clin Oncol 2005−23:205−29.
- Miller RD, Phillips MS, Jo I, et al. High-density single-nucleotide polymorphism maps of the human genome. Genomics 2005−86:117−26.
- Milligan BG. Total DNA isolation. In: Hoelzel AR (ed.). Molecular genetic analysis of populations. London: Oxford University Press, 1998−29−60.
- Minna JD, Girard L, Xie Y. Tumor mRNA expression profiles predict responses to chemotherapy. J Clin Oncol 2007−25:4329−36.
- Mouratidou D, Gennatas C, Michalaki V, et al. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Anticancer Res 2007−27:681−5.
- Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer. J Clin Oncol 2000−18:106−15.
- Loktionov A, Watson MA, Gunter M, et al. Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. Carcinogenesis 2001−22:1053−60.
- Nagle CM, Chenevix-Trench G, Spurdle AB, Webb PM. The role of glu-tathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer 2007−43:283−90.
- Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006−355:983−91.
- Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007−25:708−14.
- Peters U, Preisler-Adams S, Hebeisen A, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 2000- 11:639−43.
- Petros WP, Hopkins PJ, Spruill S. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005−23:6117−25.
- Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cis-platin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000−92:699−708.
- Pusztai L. Chips to bedside: incorporation of microarray data into clinical practice. Clin Cancer Res 2006−12:7209−14.
- Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007−33:9−23.
- Reed E. Cisplatin, carboplatin, and oxaliplatin. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy: principles and practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2006:332-^3.
- Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nature Rev Cancer 2001−1:99−108.
- Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX4 chemotherapy. J Clin Oncol 2007−25:1247−54.
- Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004−44:311−6. *
- Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001−409:928−33.
- Sandercock J, Parmar MK, Torri V, Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 2002−87:815−24.
- H5.Tinker AV, Boussioutas A, Bowtell DD. The challenges of gene expression microarrays for the study of human cancer. Cancer Cell 2006−9:333−9.
- H6.Townsend DM, Tew KD. The role of glutathione-S-transferase in anticancer drug resistance. Oncogene 2003−22:7369−75.
- H7.van den Akker-van Marie ME, Gurwitz D, Detmar SB, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thio-purine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 2006−7:783−92.
- Van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004−40:939−50.
- Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005−4:307−20.
- Wong M, Balleine RL, Collins M, et al. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 2004−75:529−38.
- Wrigley E, Verpaget HW, Jayson GC, McGown AT. Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol 2000−126:717−21.
- Yang G, Shu XO, Ruan ZX, et al. Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 2005−103:52−8.
- Yang P, Ebbert JO, Sun Z, Weinshilboum RM. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 2006−24:1761−9.
- Yu JJ, Lee KB, Mu C, et al Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000−16:555−60.
- Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004- 10:4939-^3.